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Abstract Substantial socioeconomic inequalities in breast
cancer survival persist in England, possibly due to more
advanced cancer at diagnosis and differential access to
treatment. We aim to disentangle the contributions of dif-
ferential stage at diagnosis and differential treatment to the
socioeconomic inequalities in cancer survival. Information
on 36,793 women diagnosed with breast cancer during
2000–2007 was routinely collected by an English popula-
tion-based cancer registry. Deprivation was determined for
each patient according to her area of residence at the time
of diagnosis. A parametric implementation of the media-
tion formula using Monte Carlo simulation was used to
estimate the proportion of the effect of deprivation on
survival mediated by stage and by treatment. One-third
(35 % [23–48 %]) of the higher mortality experienced by
most deprived patients at 6 months after diagnosis, and one
tenth (14 % [-3 to 31 %]) at 5 years, was mediated by
adverse stage distribution. We initially found no evidence
of mediation via differential surgical treatment. However,
sensitivity analyses testing some of our study limitations
showed in particular that up to thirty per cent of the higher
mortality in most deprived patients could be mediated by
differential surgical treatment. This study illustrates the
importance of using causal inference methods with routine
medical data and the need for testing key assumptions
through sensitivity analyses. Our results suggest that,
although effort for earlier diagnosis is important, this
would reduce the cancer survival inequalities only by a
third. Because of data limitations, role of differential sur-
gical treatment may have been under-estimated.
Keywords Breast cancer  Survival  Socioeconomic
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Introduction
Substantial socioeconomic inequalities in cancer survival
have been observed in England for decades [1–3], meaning
that many cancer deaths could be avoided [4]. For breast
cancer, besides lower screening uptake and differential
access to treatment, more advanced stage at diagnosis and
severe comorbidity are regularly proposed as the most
plausible explanatory factors of these inequalities [5, 6].
However, both factors seem to explain only part of these
inequalities, at least for breast and colorectum cancers
[7, 8].
Population-based data are crucial to understand the
mechanisms affecting all patients and to help define poli-
cies. Quantifying the proportion of the effect of deprivation
on survival that’s attributable to differential stage of
diagnosis and treatment is important for better resource
allocation to address the gap between the rich and the poor.
Methodological issues, however, are inherent to
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observational data. Most of the previous results were based
on conventional analytic approaches (e.g. by describing the
deprivation gap after adjusting for or stratifying by stage).
However, if stage and treatment are on the causal pathway
from deprivation to cancer survival, or if there is an
interaction between deprivation and the mediator(s), these
conventional approaches may lead to flaws in interpretation
[9–12]. Using methods from the causal inference literature,
we aim to disentangle the contributions of differential stage
at diagnosis and differential treatment to the socioeco-
nomic inequalities in cancer survival. To this end, we use
population-based and routinely collected data for all
patients diagnosed with a breast cancer within a defined
area.
Materials and methods
Data
We included in the analyses all women (aged 15–99 at
diagnosis) diagnosed with malignant, invasive breast can-
cer during 2000–2007, followed up until 31 December
2007, and collected by the Northern and Yorkshire Cancer
Registry Information Service (NYCRIS), a population-
based cancer registry covering 12 % of the English popu-
lation. Ascertainment of the vital status was considered to
be complete for all patients [13].
Each patient was allocated a socio-economic deprivation
score according to her area (Lower Super Output Area) of
residence at the time of diagnosis, using the English Indi-
ces of Multiple Deprivation (IMD) 2001 (income domain)
[14]. These scores were categorised according to the
quintiles of their national distribution.
Each patient was allocated one of the four broad tumor
TNM stages using a restrictive approach [15].
Information on surgical treatment was retrieved from a
routinely collected national hospital dataset (Hospital
Episode Statistics or HES). We retained surgical treatment
within 1 month before and 6 months after the cancer
diagnosis. The treatment (OPCS-4) codes [16] were cate-
gorized based on recommendations made by the Site-
Specific Clinical Reference Group (SSCRG) for breast
cancer [17] (Appendix 1). These categories were then
dichotomized into ‘major treatment’ (axillary dissection or
other axillary nodal procedures, breast conserving surgery,
mastectomy, and plastic surgery) and ‘minor or no surgery’
(other surgical procedures and none).
Analyses
We estimated net survival from breast cancer, for each
deprivation group and by stage, using the Pohar-Perme
estimator [18] implemented in the Stata [19] package stns
[20].
The assumed causal relationships between variables are
represented by a Directed Acyclic Graph (DAG) (Fig. 1,
Appendix 2). Our main exposure of interest, the patient’s
deprivation level, causally influences the age at which a
woman was diagnosed with breast cancer, her comorbidity,
thoroughness of the disease investigation, stage at diag-
nosis, the treatment received, and survival status after the
cancer diagnosis. Year and regions at diagnosis were
considered as baseline confounders. Factors such as the
quality of investigation and comorbidity (shown in grey as
unmeasured variables) were incorporated in the DAG. The
omission of variables and arrows also represents our causal
assumptions, e.g. we assume that the quality of the inves-
tigation does not affect survival except through its effect on
stage at diagnosis.
We examined what proportions of the deprivation gap in
survival were explained separately by tumor stage and
treatment. Because of our data structure (in particular, the
existence of important mediator-outcome confounders
affected by exposure, the likely presence of many inter-
actions and the fact that our outcome is binary) we focused
on the decomposition of the total causal effect (TCE) into
what have recently been termed randomized interventional
analogues of natural direct and indirect effects, henceforth
RIANDE and RIANIE [21–23].
The RIANDE and RIANIE can be estimated with an
extension of Robins’ g-computation formula [24] imple-
mented using Monte Carlo simulation in the Stata com-
mand gformula [25]. We chose this method because of
flexible modelling that allows interactions and other non-
linearities. Although flexible in terms of parametric mod-
elling assumptions, this method relies on the assumptions
of no unaccounted confounding of the exposure–mediator,
mediator–outcome or exposure–outcome relationship.
We conducted three analyses to investigate the mediat-
ing roles of stage and treatment (Appendix 3, Appendix 4).
We first estimated the proportion of the effects of depri-
vation on survival that was mediated by differences in
stage at diagnosis, i.e. we computed the ratio between the
effect of deprivation on log odds of death that was medi-
ated by stage (the RIANIE) and the total effect of depri-
vation on log odds of death (the total causal effect, TCE,
which is the sum of the RIANDE—the effect not mediated
by the mediator stage—and the RIANIE). In the second
analysis, we estimated the proportion of the effect of
deprivation on log odds of death that was mediated by
differences in treatment. Stage at diagnosis was here con-
sidered to be a confounder of the relationship between
treatment and survival, and was allowed to be affected by
deprivation. Such a confounder is dealt with using an
extension of the g-computation formula [24, 25]. In the
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third analysis, we estimated the proportion of the effect of
deprivation on treatment that is mediated by differential
stage.
Because the deprivation gap in survival varies by time
since diagnosis, the binary survival outcome (dead vs.
alive) was stratified according to time since diagnosis: at
6 months, 1 year given (conditioning on) 6-month survival,
3 years given 1-year survival, and 5 years given 3-year
survival. The analyses were performed separately on each
of these four binary survival outcomes, in order to disen-
tangle early from late mediating effects of stage and
treatment on deprivation gap in survival.
We used multinomial regressions to model stage at
diagnosis (four categories) and logistic regression for
treatment and survival status. Age at diagnosis was mod-
elled using restricted cubic splines [26].
Single stochastic imputation within the g-computation
procedures was used to handle missing stage (8 %). All
variables in the models (including vital status), exact length
of follow-up times and detailed treatment categories were
included in the imputation model.
Results
We analyzed 36,793 women diagnosed with breast cancer
between 2000 and 2007 in Yorkshire and North East
(Table 1). More deprived patients were diagnosed at an
older age (P = 0.001) and a more advanced stage
(P\ 0.001) than the more affluent. The higher the depri-
vation level, the more advanced the stage.
Survival from breast cancer
Net survival differed between the most affluent and the
most deprived patients by 3 % at 1 year (97 vs. 94 %), and
10 % at 5 years (86 vs. 76 %) after diagnosis (Fig. 2,
Appendix 5).
Stage-specific survival estimates were consistently
lower in the more deprived patients. Large deprivation gap
existed for the short-term survival (at 1 year after diagno-
sis) in the most advanced stage (IV), and in the long-term
survival (at 5 years) in the less advanced stages (II–III).
For patients with missing stage information, the more
deprived experienced worse survival.
Total effect of deprivation on cancer survival status
We first estimated the total causal effect of deprivation on
survival status, which is the sum of all effects shown in
Fig. 1, adjusted for the confounding effect of region and
year of diagnosis. The odds of dying within the first
6 months since diagnosis roughly increased linearly with
increasing deprivation (odds ratio [OR] comparing most
deprived to most affluent patients: 2.77, 95 % confidence
interval [CI] 2.17, 3.53) (Fig. 3a, Appendix 6). This depri-
vation effect decreased slightly as follow-up time increased.
However, the effect remained fairly strong at 5 years
Fig. 1 Direct Acyclic
Diagram (DAG) depicting the
causal relationships between
deprivation and survival status
in breast cancer patients. Year
of diagnosis and region are
considered as baseline
confounders, with potentially an
arrow to each node in the
diagram, and thus are not shown
in this DAG
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Table 1 Characteristics of women diagnosed with breast cancer, Yorkshire and North East (England), 2000–2007
All patients Deprivation
Least deprived 2 3 4 Most deprived
Number of patients 36,793 6411 7549 6982 7642 8209
% Alive at end of follow-up 78.9 85.1 81.2 79.2 76.7 73.6
Mean age at diagnosis 62.9 61.0 61.3 62.4 63.1 63.7
(interquartile range) 51.9–73.9 51.2–70.3 51.8–72.7 52.1–74.3 52.1–75.7 52.2–75.2
Stage at diagnosis (%)
I 37.6 40.9 38.8 38.0 36.3 34.8
II 43.0 43.7 43.9 41.7 42.5 43.1
III 6.8 6.2 6.2 7.0 7.0 7.4
IV 4.6 3.5 3.7 4.6 5.0 5.9
Missing 8.0 5.7 7.4 8.7 9.2 8.8
% Receiving major treatment 26.9 25.9 25.7 27.6 27.1 28.0
Fig. 2 Net survival by deprivation and stage at diagnosis, women diagnosed with breast cancer, Yorkshire and North East (England), 2000–2007
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conditioning on 3-year survival (for most deprived com-
pared with least deprived, OR: 1.67, 95 % CI 1.39, 2.00).
Role of stage on the socio-economic differences
in cancer survival status
The effect of socioeconomic status on survival mediated
through stage (the RIANIE, Fig. 3b) was only apparent
when comparing the most deprived with the least deprived.
This indirect effect through stage decreased as time since
diagnosis increased (OR for 6-month mortality: 1.43, CI:
1.27, 1.62; OR for 5-year conditional mortality: 1.08, CI
1.00, 1.16) (Fig. 3b). On the log odds scale, stage only
accounted for about one-third of the total effect of depri-
vation at 6-month and 1 year (proportion mediated [PM]:
35 %, CI 23, 48 %; 30 %, CI 5, 54 %, respectively), a
proportion which decreased to just over a tenth at 3 and
5 years since diagnosis (PM: 12 %, CI 4, 21 %; 14 %, CI
-3, 31 %, respectively) (Appendix 6).
We also treated both age and stage as mediators (in
place of just stage). We assumed here linear associations
between the logarithm of age and treatment or mortality.
The overall pattern hardly changed although adding age
tended to slightly increase the long-term PM. This might
reflect the long-term effect of age on all-cause mortality
(Appendix 6).
Role of treatment on the socio-economic differences
in cancer survival status
The higher the stage, the less likely a patient would receive
major surgical treatment (Fig. 4). For patients under
70 years when diagnosed with early stages (stages I and II),
more deprived patients received more treatment. By con-
trast, for patients aged 70 and over, more deprived patients
received less treatment for all stages.
We did not find any evidence for total effect of depri-
vation and effect mediated by stage on treatment (Ap-
pendix 8). Although treatment patterns differ between
different socioeconomic classes, the main mediation anal-
ysis found no evidence for the effect of deprivation on
mortality mediated through differential treatment (Fig. 3c,
Appendix 7).
Discussion
Our results suggest that, for the most deprived patients
only, earlier breast cancer diagnosis would reduce the
deficit in short-term survival by up to a third and in longer-
term survival by up to a tenth. The available crude infor-
mation on treatment seems to show that differential sur-
gical treatment between deprivation groups played a minor
Fig. 3 Effect of deprivation on odds of deaths at different times since
breast cancer diagnosis, results from the G-computation Analyses.
(a) Shows the total effect of increasing deprivation on odds of death.
(b) shows the effect that were mediated via stage at diagnosis, and
(c) shows the effect mediated via surgical treatment. Odds of death at
12 months since diagnosis are conditional on surviving the first
6 months after cancer diagnosis. Similarly, odds of death at 3 years
are conditional on survival the first 12 months; odds of death at
5 years are conditional on survival the first 3 years. We used
conditional odds of death in order to disentangle early from late
mediating effects of stage and treatment on deprivation gap in
survival
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role in socioeconomic inequalities in breast cancer
survival.
For the younger (15–69) patients diagnosed at stage I or
II, the finding that more deprived patients received more
treatment contradicts the a prior hypothesis by some
oncologists: more deprived patients may have more
comorbidity, and thus less aggressive diagnostic investi-
gation and treatment. Prevalence of both obesity and
tobacco smoking widely varies in the general population
between deprivation groups [27, 28], but we did not have
reliable information about comorbidity of the cancer
patients. However, the surgical differences observed
between the socioeconomic groups may reflect that, within
a given stage, more deprived patients were diagnosed with
more advanced disease. To investigate this hypothesis, we
will need more detailed information on tumor stage and
diagnostic investigation. In addition, more affluent patients
may have received treatment within private facilities,
information not available to us.
In the absence of individual measure of socioeconomic
status for population-based studies in England, we used an
ecological measure of deprivation [14]. Because LSOAs
(the geographical level of the deprivation measure) are
relatively small (1500 inhabitants on average) and have
been made as socially homogenous as possible, the eco-
logical bias is probably small. An ecological measure
reflects both the individual and contextual dimensions of
deprivation. We are not able to disentangle individual and
contextual dimensions of deprivation and this affects con-
ceptualizing hypothesized interventions. The English
healthcare system is strongly territorialised, and any per-
ceived intervention should primarily target these territories
in which individual-level actions (via the general practices)
are also possible. Such interventions correspond to our
conceptual framework, i.e. we asked: what would be the
outcome of women in the deprived group, had they lived in
the same area as those lived in the most affluent areas, with
similar background risk factors and access to primary and
secondary healthcare for their cancer diagnosis and
treatment.
We identified three main plausible reasons that could
bias our results: misclassification of the stage at diagnosis,
misclassification of the treatment and unmeasured con-
founders between the mediator(s) and the outcome(s).
Misclassification of stage at diagnosis
More deprived cancer patients may more likely be man-
aged by non-specialized centres and low-workload sur-
geons [29]. Evaluating the spread of their cancers (i.e.
staging) may not be thorough enough (Fig. 1) and, as a
result, they might be more often under-staged and receive
non-optimal treatment [8]. We tested this hypothesis by
assuming different proportions of the most deprived
patients were under-staged. We randomly up-staged 10, 30
and 50 % of the most deprived patients by one level (stage
I to II, etc.) ten times and reran the analyses to estimate the
PM distributions. The proportion of survival inequalities
mediated by stage hardly changed with 10 % of under-
staged most deprived patients, but increased substantially
with 30 and 50 % of under-staged, more particularly for
conditional survival at 1 year and over (data on request).
For example, more than half of the lower conditional
1-year survival among the most deprived patients would be
mediated by stage if above 30 % of them were under-
staged (vs. 30 % mediated if stage was not misclassified).
Changing our main conclusion about the role of stage on
survival inequalities would require above 30 % of the most
deprived patients were systematically under-staged, com-
pared to none in the most affluent group, a rather extreme
assumption that is not supported by the literature.
Fig. 4 Probability of receiving major surgery for women diagnosed
with breast cancer, Yorkshire and North East (England), 2000–2007
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Misclassification of treatment
Surgery, often in conjunction with other treatments,
remains the main curative treatment of breast cancer.
Information on radiotherapy and chemo/hormono-therapy
was too poor to be used here. The quality, completeness
and intention (whether curative or not) of the surgical
procedure were not known. It was reported that 3.6 % of
surgical treatment for breast cancer were made in private
hospital in NYCRIS [30]. Such under-estimation of the
surgery proportion is likely to affect primarily the more
affluent patients. We conducted a sensitivity analysis to
investigate how such misclassification would influence the
mediating effect of treatment on the socioeconomic dif-
ferences in breast cancer survival. We randomly changed
the treatment status for 3.6 % of the patients from no/minor
surgical procedures to major surgery, according to the stage
and age distribution of those who had records of receiving
major treatment. We assumed that those patients were
entirely from the most affluent group. We generated 100
new datasets on which we carried out g-computation
analyses, estimating the proportion of effect of deprivation
on survival mediated by treatment. We confirmed the
absence of indirect effect through differential treatment on
cancer survival status for deprivation groups 2–4. How-
ever, treatment did mediate around 30–40 % of the dif-
ferential mortality between the most deprived patients and
the most affluent, regardless time since diagnosis (Fig. 5),
under the assumption that only the most affluent patients
had surgeries in private hospitals. In addition, around 10 %
of the cancer registry cases could not be matched with HES
(inpatient data from the National Health Services) [30].
Surgical information is likely to be missing completely at
random for such patients and we do not expect this to bias
our results.
Our analyses crudely dichotomized treatment into ‘ma-
jor’ and ‘minor or no’ surgery categories. When ‘major’
surgery was further categorized into ‘breast conserving
surgery’ and ‘mastectomy’, the results remained unchan-
ged (Appendix 7). Nevertheless, the crude treatment
information may explain why the mediating effect of
treatment on deprivation gap in survival remained moder-
ate and was not affected in the sensitivity analysis on the
misclassification of tumor stage.
Unmeasured confounders
We assumed that, conditional on deprivation, age, stage
and year at diagnosis, and government regions, there were
no further (unmeasured) common causes of treatment and
survival status. However, in addition to staging thorough-
ness, comorbidity could be an important confounder for
treatment and mortality, which we did not account for due
to lack of reliable individual information. Ignoring the
confounding effect of comorbidity would potentially lead
to over-estimation of the beneficial effect of major surgery
on mortality: patients with high levels of comorbidity
experience high mortality, and may have lower rate of
major surgery. Since we found little evidence for treatment
to mediate the effect between deprivation and mortality in
the original dataset, inclusion of comorbidity would not
change this overall interpretation, but only if stage and
Fig. 5 Proportion of the effect
of deprivation on odds of death
mediated by treatment in a
sensitivity analysis taking into
account of the potentially
missing surgical information
due to treatment in private
hospitals
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treatment were not misclassified. If reliable information on
comorbidity becomes available, we could potentially treat
it as a mediator between deprivation and mortality, and
estimate how much contribution it has to the deprivation
gap in survival.
Concluding remarks
Our results are based on population-based data, i.e. on
virtually all patients diagnosed with a breast cancer in a
given region, including those who were diagnosed with
advanced stage and those who were not optimally man-
aged. Since our main focus is to better understand the
causal relationships between deprivation and breast cancer
survival, and to divide it into path-specific components,
applying methods from the growing literature on causal
mediation is highly appropriate.
To our knowledge, very few studies attempted to dis-
entangle the effects of deprivation on breast cancer sur-
vival. Two studies used data from an earlier periods (late
1990s) of the same region as our study [31, 32]. A com-
plete-case analysis found adverse stage distribution and
less surgical treatment (even after adjustment for stage)
among more deprived patients [31]. No stage-specific
results were provided on treatment. Lower overall 5-year
survival was associated with deprivation after adjustment
for age and stage, but underlying pathways could not be
deduced from these results. A second analysis using latent
class modelling [32] clearly identified two groups of
patients according to their prognosis: more advanced
stage seemed to play a role in the deprivation gap in
5-year survival only in one group. The conclusions were
weakened by the fact that overall survival was analysed,
while mortality from causes other than breast cancer
varies greatly by deprivation within 5 years since diag-
nosis. Our study is also based on overall mortality. Not
adjusting for competing risks of death will dilute the
mediating effect of stage. However, this effect would be
minimal for short-term survival, as mortality from causes
not related to breast cancer does not play a significant role
in short-term survival status, especially at 6 months after
diagnosis. Using conditional survival also reduced this
bias.
Contrasting with our results, a study in another English
region found that, in 2006–2010, adverse stage distribution
explained half of the deficit in 5-year breast cancer relative
survival observed among the most deprived patients, but all
of it in other deprivation groups [33]. However, stage-s-
tandardisation, used in order to eliminate differences in
stage distribution by deprivation, cannot fully identify the
effect of deprivation mediated by tumor stage on such
observational data.
Applying another causal inference approach, Valeri
et al. [34] found that the contribution of stage to the dis-
parities in survival from colorectal cancer between Blacks
and Whites in the US was similar to our results for the
socio-economic disparities in breast cancer survival in
England. They however concluded that the mediation
effect of stage represented a ‘‘substantial reduction’’ while
we talked about a small reduction, which reflects differ-
ences in the study context. Contrasting with the US (at least
until recently), the healthcare system in England is uni-
versal with free access to diagnosis and treatment. In the-
ory, most disparities in cancer survival should be therefore
due to patient and tumour factors, more specifically tumour
stage at diagnosis and comorbidity, and not to healthcare
system factors. Contrasting this belief, our results add to
the growing evidence that one of the strongest prognostic
factors, stage, plays a relatively small role in the socio-
economic inequalities in cancer survival. Comorbidity (or
health performance status) is likely to contribute to
inequalities, but will reduce the stage contribution esti-
mated further. It means that, in the context of a supposedly
equitable healthcare system, a large proportion of these
inequalities remain unexplained; inequalities within the
healthcare system are likely to play a key role.
Despite data limitations, we were able to estimate the
proportions of the deprivation gap in cancer survival
mediated via tumor stage and treatment separately. It
informs us about their respective roles, and ultimately,
what may be done to most effectively reduce the depriva-
tion gap in cancer survival. In particular, effort for earlier
diagnosis would reduce the cancer survival inequalities
only by a third. Our conclusions may, however, be altered
by unmeasured confounders such as comorbidity, staging
thoroughness and detailed treatment information, of which
quality and completeness are improving dramatically in the
population-based cancer registry data in England. The
changes in results after sensitivity analyses demonstrate the
vital importance of using reliable and correctly classified
surgical treatment data in similar studies.
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